| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9642913 | NEURELIS INC | Pharmaceutical composition including alkyl glycoside and an anti-seizure agent |
May, 2025
(1 year, 13 days from now) | |
| US10265402 | NEURELIS INC | Absorption enhancers for drug administration |
May, 2025
(1 year, 13 days from now) | |
| US8927497 | NEURELIS INC | Absorption enhancers for intranasal administration |
Jul, 2025
(1 year, 2 months from now) | |
| US11793786 | NEURELIS INC | Administration of benzodiazepine compositions |
Mar, 2029
(4 years from now) | |
| US9763876 | NEURELIS INC | Administration of benzodiazepine compositions |
Mar, 2029
(4 years from now) | |
| US11241414 | NEURELIS INC | Administration of benzodiazepine compositions |
Mar, 2029
(4 years from now) | |
| US8895546 | NEURELIS INC | Administration of benzodiazepine compositions |
Mar, 2029
(4 years from now) | |
Valtoco is owned by Neurelis Inc.
Valtoco contains Diazepam.
Valtoco has a total of 7 drug patents out of which 0 drug patents have expired.
Valtoco was authorised for market use on 10 January, 2020.
Valtoco is available in spray;nasal dosage forms.
Valtoco can be used as nasal administration of diazepam for treatment of intermittent, stereotypic episodes of frequent seizure activity in patients 6 years of age and older.
The generics of Valtoco are possible to be released after 27 March, 2029.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-279) | Jan 10, 2027 |
| New Product(NP) | Jan 10, 2023 |
Drugs and Companies using DIAZEPAM ingredient
Market Authorisation Date: 10 January, 2020
Treatment: Nasal administration of diazepam for treatment of intermittent, stereotypic episodes of frequent seizure activity in patients 6 years of age and older
Dosage: SPRAY;NASAL
VALTOCO family patents
